Cryo-Electron Microscopy Reveals Architecture of the BAF Complex.

Abstract:

:The structure of the chromatin-remodeling BAF complex provides molecular-scale mechanistic insight.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-RW2020-020

subject

Has Abstract

pub_date

2020-03-01 00:00:00

pages

339

issue

3

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-RW2020-020

journal_volume

10

pub_type

评论,杂志文章
  • Tetanus shot may improve glioblastoma treatment.

    abstract::Preconditioning the immune system with a tetanus/diphtheria toxoid significantly improved the effectiveness of dendritic cell immunotherapy and extended overall survival in a small, randomized study of patients with glioblastoma. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-NB2015-053

    authors:

    更新日期:2015-06-01 00:00:00

  • Tweaking Transcription to Stop AML Cell Growth.

    abstract::A new compound with anti-leukemia activity perturbs gene transcription by modulating super-enhancer activity. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-149

    authors:

    更新日期:2015-12-01 00:00:00

  • Combo Therapy for Lung Cancer Extends Survival.

    abstract::The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non-small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in p...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2018-051

    authors:

    更新日期:2018-06-01 00:00:00

  • Metastasis Has Multiple Origins and Occurs Early in Tumorigenesis.

    abstract::Whether metastases were seeded mono- or polyclonally depended on cancer site and treatment. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-082

    authors:

    更新日期:2020-07-01 00:00:00

  • Lower Airway Dysbiosis Affects Lung Cancer Progression.

    abstract::In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly occurs, and ex vivo models support that some of these bacteria can trigger host transcriptomic signatures associated with carcinogenesis. Here, we show that this lower airway dysbiotic signature was more prevalent in the stage IIIB...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-20-0263

    authors: Tsay JJ,Wu BG,Sulaiman I,Gershner K,Schluger R,Li Y,Yie TA,Meyn P,Olsen E,Perez L,Franca B,Carpenito J,Iizumi T,El-Ashmawy M,Badri M,Morton JT,Shen N,He L,Michaud G,Rafeq S,Bessich JL,Smith RL,Sauthoff H,Fel

    更新日期:2020-11-11 00:00:00

  • Myelodysplastic Syndrome Splicing Factor Mutations Induce R-Loops.

    abstract::Mutations in SRSF2 and U2AF35 trigger replication stress and ATR activation via R-loop formation. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-RW2018-025

    authors:

    更新日期:2018-04-01 00:00:00

  • Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

    abstract::We performed cytosine methylation sequencing on genetically diverse patients with acute myeloid leukemia (AML) and found leukemic DNA methylation patterning is primarily driven by nonpromoter regulatory elements and CpG shores. Enhancers displayed stronger differential methylation than promoters, consisting predominan...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-16-1032

    authors: Glass JL,Hassane D,Wouters BJ,Kunimoto H,Avellino R,Garrett-Bakelman FE,Guryanova OA,Bowman R,Redlich S,Intlekofer AM,Meydan C,Qin T,Fall M,Alonso A,Guzman ML,Valk PJM,Thompson CB,Levine R,Elemento O,Delwel R,Meln

    更新日期:2017-08-01 00:00:00

  • From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer.

    abstract::DNA repair deficiencies are common among cancer cells and represent a potential vulnerability that might be exploited by targeting compensatory repair pathways. However, the identification of synthetically lethal combinations of DNA repair defects, although of significant clinical relevance, has been somewhat anecdota...

    journal_title:Cancer discovery

    pub_type:

    doi:10.1158/2159-8290.CD-14-0316

    authors: Hemann MT

    更新日期:2014-05-01 00:00:00

  • Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukaemia.

    abstract::Internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITD) occurs in 30% of poor prognosis acute myeloid leukaemias (AMLs). Limited clinical efficacy of FLT3 inhibitors highlights the need for alternative therapeutic modalities in this subset of disease. Using human and murine models of FLT3-ITD-dri...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-20-0738

    authors: Bjelosevic S,Gruber E,Newbold A,Shembrey C,Devlin JR,Hogg SJ,Kats L,Todorovski I,Fan Z,Abrehart TC,Pomilio G,Wei A,Gregory GP,Vervoort SJ,Brown KK,Johnstone RW

    更新日期:2021-01-12 00:00:00

  • Pembrolizumab Approved for Hodgkin Lymphoma.

    abstract::The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers-and for children. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-044

    authors:

    更新日期:2017-05-01 00:00:00

  • Cancer "Clock" Opens New Therapeutic Avenues.

    abstract::Long ignored, the importance of circadian rhythms-the focus of this year's Nobel Prize in Physiology or Medicine-is beginning to gain attention from researchers interested in cancer prevention, drug discovery, and therapeutic optimization. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-149

    authors:

    更新日期:2017-12-01 00:00:00

  • LKB1 Inactivation Promotes ROS-Induced Plasticity in NSCLC.

    abstract::LKB1 inactivation generates a redox imbalance that promotes ADC-to-SCC transdifferentiation in NSCLC. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2015-089

    authors:

    更新日期:2015-07-01 00:00:00

  • Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

    abstract::E3 ubiquitin ligases are of interest as drug targets for their ability to regulate protein stability and function. The oncogene Mdm2 is an attractive E3 ligase to target, as it is the key negative regulator of the tumor suppressor p53, which controls the transcription of genes involved in cell fate. Overexpression of ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0104

    authors: Herman AG,Hayano M,Poyurovsky MV,Shimada K,Skouta R,Prives C,Stockwell BR

    更新日期:2011-09-01 00:00:00

  • iRECIST Guideline Unveiled for Immunotherapies.

    abstract::The new iRECIST guideline-developed in consultation with academics, drug companies, and regulatory authorities-provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kin...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-NB2017-037

    authors:

    更新日期:2017-05-01 00:00:00

  • Tumor Profiling: Adding Proteomics to Genomics.

    abstract::Researchers have used mass spectrometry to conduct proteomic analyses of 77 genomically characterized breast tumors. Through this approach, they've uncovered functional consequences of somatic mutations. For instance, EGFR overexpression in basal-like breast cancer is potentially driven by the loss of two genes, SKP1 ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-078

    authors:

    更新日期:2016-08-01 00:00:00

  • Gilead Buying Kite for $11.9 Billion.

    abstract::Gilead Sciences will buy Kite Pharma-and its autologous CAR T-cell technology-for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-123

    authors:

    更新日期:2017-10-01 00:00:00

  • Improved survival ends nivolumab trial early.

    abstract::A phase III trial testing nivolumab to treat advanced melanoma was stopped early due to improved overall survival compared with standard chemotherapy. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-NB2014-104

    authors:

    更新日期:2014-09-01 00:00:00

  • Protective effect of aspirin associated with SNP.

    abstract::According to findings of a study in the Journal of the National Cancer Institute, people with a single-nucleotide polymorphism on chromosome 8q24 who regularly use aspirin can cut their risk of colorectal cancer by about half. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2014-011

    authors:

    更新日期:2014-03-01 00:00:00

  • Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.

    abstract:: In this study, McKeown and colleagues carried out a genome-wide characterization and stratification of the enhancer landscape in acute myeloid leukemia (AML). The authors' analysis led to the discovery of a novel RARA superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sens...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-17-0860

    authors: Wang E,Aifantis I

    更新日期:2017-10-01 00:00:00

  • Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

    abstract::An increasing number of anticancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Recent evidence suggests that the selection of patients whose tumors harbor specific genetic alterations identifies the subset of patients who are most likely to benefit from the use ...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-11-0110

    authors: MacConaill LE,Van Hummelen P,Meyerson M,Hahn WC

    更新日期:2011-09-01 00:00:00

  • RNA Missplicing Triggers Antiviral Immune Response in Breast Cancer.

    abstract::Spliceosome inhibitors induced mRNA missplicing, retaining introns that formed double-stranded RNA. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2021-008

    authors:

    更新日期:2021-01-22 00:00:00

  • A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

    abstract:UNLABELLED:Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients with prostate cancer, acquired resistance invariably emerges. To identify the molecular mechanisms underlying acquired resistance, we developed and characterized cell lines resistant to ARN-50...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-13-0226

    authors: Joseph JD,Lu N,Qian J,Sensintaffar J,Shao G,Brigham D,Moon M,Maneval EC,Chen I,Darimont B,Hager JH

    更新日期:2013-09-01 00:00:00

  • Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses.

    abstract::Although BRAF-MEK inhibition can enhance the immune recognition of melanoma cells, the mechanisms that underlie this remain poorly defined. In this issue of Cancer Discovery, Erkes and colleagues present new data showing that BRAF-MEK inhibition activates pyroptosis in melanoma cells through gasdermin E cleavage, lead...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-19-1441

    authors: Smalley KSM

    更新日期:2020-02-01 00:00:00

  • Olaparib shows promise in multiple tumor types.

    abstract::A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2013-082

    authors:

    更新日期:2013-07-01 00:00:00

  • Enzalutamide Bests Older NSAAs in mHSPC.

    abstract::According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-066

    authors:

    更新日期:2019-08-01 00:00:00

  • Forty years of translational cancer research.

    abstract::Forty years after the signing of the National Cancer Act, we have produced a stunning repository of scientific information that is being translated into better therapies for patients. Although challenges remain, many solutions have been adopted, leading to early signs of progress against some of humankind's most dread...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0196

    authors: Hait WN

    更新日期:2011-10-01 00:00:00

  • Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.

    abstract::Oncogenic KRAS (KRAS*) is a key tumor maintenance gene in pancreatic ductal adenocarcinoma (PDAC), motivating pharmacologic targeting of KRAS* and its effectors. Here, we explored mechanisms involving the tumor microenvironment (TME) as a potential basis for resistance to targeting KRAS*. Using the inducible KrasG12D;...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0597

    authors: Hou P,Kapoor A,Zhang Q,Li J,Wu CJ,Li J,Lan Z,Tang M,Ma X,Ackroyd JJ,Kalluri R,Zhang J,Jiang S,Spring DJ,Wang YA,DePinho RA

    更新日期:2020-07-01 00:00:00

  • PD-L1 blockade maintains irradiation-mediated antitumor immunity.

    abstract::Ionizing irradiation and PD-L1 blockade synergistically enhance antitumor immunity. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-RW2014-012

    authors:

    更新日期:2014-03-01 00:00:00

  • Hypoxia signaling--license to metastasize.

    abstract::Hypoxia-inducible factors (HIF) have long been linked to malignant tumor phenotypes in various cancer types, and several downstream mediators of HIF action are deregulated in metastatic carcinomas. A new study links hypoxia-induced collagen remodeling to sarcoma progression, providing evidence for unifying mechanisms ...

    journal_title:Cancer discovery

    pub_type: 评论

    doi:10.1158/2159-8290.CD-13-0481

    authors: Vanharanta S,Massagué J

    更新日期:2013-10-01 00:00:00

  • Evolutionary pathways in BRCA1-associated breast tumors.

    abstract::BRCA1-associated breast tumors display loss of BRCA1 and frequent somatic mutations of PTEN and TP53. Here we describe the analysis of BRCA1, PTEN, and p53 at the single cell level in 55 BRCA1-associated breast tumors and computational methods to predict the relative temporal order of somatic events, on the basis of t...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0325

    authors: Martins FC,De S,Almendro V,Gönen M,Park SY,Blum JL,Herlihy W,Ethington G,Schnitt SJ,Tung N,Garber JE,Fetten K,Michor F,Polyak K

    更新日期:2012-06-01 00:00:00